Modified exosomes for targeted delivery of doxorubicin and carvedilol to mitochondria in breast cancer cells.

ABSTRACT: Carvedilol (CAR), a well-established β-blocker and a promising pharmacological agent for mitigating doxorubicin (DOX)-induced cardiotoxicity, has also demonstrated anticancer effects against breast cancer cells. Given the seemingly contradictory effects of CAR and DOX treatment on cardiomyocytes and cancer cells, particularly regarding mitochondrial function, this study investigates the synergistic potential of DOX and CAR through various delivery systems, including free form, exosomal formulations, and mitochondria-targeted delivery systems. The Chou-Talalay analysis demonstrated that combining DOX with CAR at a 1:1 ratio reduced DOX's IC50 in MCF-7 (from 0.274 µM to 0.191 µM) and MDA-MB-231 (from 0.138 µM to 0.086 µM) cells. Drug loading in exosomal formulations was achieved with approxi

SUBMITTER: Soudi T 

PROVIDER: S-EPMC12583512 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature